Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Inmaculada Ramos García, Johan Vansteenkiste et al.|The Lancet Oncology|2018Cited by 579
A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).Afshin Dowlati, Luis Paz-Ares Rodríguez, Raffaele Califano et al.|Journal of Clinical Oncology|2026Cited by 1